The kinase NIK as a therapeutic target in multiple myeloma

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.15, Iss.2, 2011-02, pp. : 207-218

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma

Current Pharmaceutical Design, Vol. 20, Iss. 1, 2014-01 ,pp. : 125-135

Bentham Science Publishers

Access to resources Recommend Favorite

CCR1 as a target for multiple myeloma

By Vallet Sonia Anderson Kenneth C

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 9, 2011-09 ,pp. : 1037-1047

Informa Healthcare

Access to resources Recommend Favorite

Antiangiogenic Therapeutic Approaches in Multiple Myeloma

Current Cancer Drug Targets, Vol. 12, Iss. 7, 2012-09 ,pp. : 768-775

Bentham Science Publishers

Access to resources Recommend Favorite

Anaplastic lymphoma kinase as a therapeutic target

By Kruczynski Anna Delsol Georges Laurent Camille Brousset Pierre Lamant Laurence

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 11, 2012-11 ,pp. : 1127-1138

Informa Healthcare

Access to resources Recommend Favorite

Current therapeutic uses of lenalidomide in multiple myeloma

By Hideshima Teru Richardson Paul G Anderson Kenneth C

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 2, 2006-02 ,pp. : 171-179

Informa Healthcare

Access to resources Recommend Favorite